Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

49.37 +0.47 (+0.96%)
Streaming Delayed Price Updated: 11:27 AM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
39 40 Next >
News headline image
Sonos, Bumble And Some Other Big Stocks Moving Lower In Today's Pre-Market Session ↗
 
Via Benzinga
News headline image
WeTrade, Roblox And Some Other Big Stocks Moving Lower On Wednesday ↗
  OptimizeRx Corporation (NASDAQ: OPRX) shares fell 26.7% to $16.32 after the company reported worse-than-expected Q2 EPS and sales results and issued FY22 sales guidance below estimates. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  During Wednesday, 52 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Sanofi, Innovent Biologics Collaborate On Cancer Treatments In China ↗
 
Via Benzinga
News headline image
Sanofi Ekes Out Narrow Beat As Eczema Giant Scores Massive Gain ↗
The company reported more than 40% growth for Dupixent in the second quarter. 
Via Investor's Business Daily
News headline image
Sanofi (NASDAQ:SNY) Shareholder Notice: Investigation Concerning Possible Violations of Securities Laws ↗
San Diego, CA -- (SBWIRE) -- 08/09/2022 -- Sanofi is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Monkeypox Plays Jockey For Position This Week
Via AB Newswire
News headline image
Looking Into Sanofi's Recent Short Interest ↗
Sanofi's (NASDAQ:SNY) short percent of float has fallen 25.0% since its last report. The company recently reported that it has 2.31 million shares sold short, which is 0.09% of... 
Via Benzinga
News headline image
How Siga Is Turning Its Biowarfare Soldier Onto This Outbreak ... And The Next ↗
Siga stock more than tripled, emerging from under the radar to take on the outbreak. 
Via Investor's Business Daily
News headline image
Regeneron's Prostate Cancer Combo Candidate Shows Encouraging Anti-Tumor Activity ↗
 
Via Benzinga
News headline image
A Bearish Sign Appears On Sanofi's Chart ↗
If history is any guide, there may be trouble ahead for shares of Sanofi (NASDAQ:SNY). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock. 
Via Benzinga
News headline image
Sanofi Raises Annual Guidance On Upbeat Q2 Performance ↗
 
Via Benzinga
News headline image
Daily Stock Analysis: Sanofi S.A. ↗
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. It was founded in 1973 and is headquartered in Paris. 
Via Talk Markets
News headline image
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
3-D Portfolio: Discounts, Diversification, And Dividends ↗
When it comes to high-yield closed-end funds, I’m a big fan of the “three Ds” — discounts, diversification, and dividends. Today, we’ll look at a three-fund, bargain-priced “3-D” CEF portfolio you can... 
Via Talk Markets
News headline image
Week In Review: China Biopharma Tops $2.8 Billion In Week's Dealmaking ↗
CSPC Pharma out-licensed global rights for its antibody drug conjugate targeting Claudin18.2 to Elevation Oncology of New York City. CSPC will receive a $27 million upfront payment and up to $148... 
Via Talk Markets
News headline image
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
A Monoclonal Antibody Treatment For ALS Could Begin Human Trials By 2023, According To Pasithea ↗
Pasithea Therapeutics Corp. (NASDAQ: KTTA), a biotech company looking for new treatments for psychiatric and neurological disorders, received an AU$1 million (US$694,000) gran 
Via Benzinga
News headline image
Earnings Outlook For Sanofi ↗
Sanofi (NASDAQ:SNY) is set to give its latest quarterly earnings report on Thursday, 2022-07-28. Here's what investors need to know before the announcement. Analysts estimate that Sanofi will report an... 
Via Benzinga
News headline image
Regeneron's Price Target Cut On Dim Prospects For Its Flagship Eye Product ↗
 
Via Benzinga
News headline image
Earnings Scheduled For July 28, 2022 ↗
Companies Reporting Before The Bell • ArcelorMittal (NYSE:MT) is estimated to report earnings for its second quarter. 
Via Benzinga
News headline image
Amid RNA Setbacks, Start Up Bets On Sanofi's siRNA Platform ↗
 
Via Benzinga
News headline image
Apple, Meta, Pfizer Among Key Companies Reporting In The Week Ahead, As Earning Picks Up Pace ↗
Big tech earnings will flow in thick and fast in the upcoming week, providing more clarity on how supply chain disruptions and the macroeconomic malaise have impacted these companies. 
Via Benzinga
News headline image
Pasithea's Latest Drug Candidate Could Bring New Hope To ALS Patients Without Effective Treatment Options ↗
Amyotrophic lateral sclerosis (ALS) is a rare but painful and fatal disease that slowly shuts down all voluntary movements in the body, from walking to breathing. 
Via Benzinga
News headline image
Analyzing Sanofi's Short Interest ↗
Sanofi's (NASDAQ:SNY) short percent of float has fallen 14.29% since its last report. The company recently reported that it has 3.00 million shares sold short, which is 0.12% of... 
Via Benzinga
News headline image
Clovis Oncology (CLVS) Stock Pops 7% on Supply Agreement ↗
CLVS stock is rallying 7% after Clovis Oncology made a major deal with NorthStar Medical. Takeover speculation has swirled around Clovis. 
Via InvestorPlace
News headline image
The Daily Biotech Pulse: Sesen Bio Stops Lead Assest Development In US, FDA Approves Eton Pharma's Partial Seizures Drug, Bavarian Nordic Inks Multiple Supply Pact For Monkeypox Vaccine ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Regeneron-Sanofi's Dupixent Hits Primary Goal In Esophagitis Patients Below 11 Years ↗
 
Via Benzinga
News headline image
Sanofi Offloads 17 Products To Neuraxpharm ↗
Sanofi SA (NASDAQ: SNY) has entered a deal to hand over 17 products to central nervous system (CNS) specialist Neuraxpharm for an undisclosed sum.  
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.